Drug Trial Radar · NCT04610541
REMdesivir-HU Clinical Study and Severe Covid-19 Patients
Last checked: Nov 20, 2026Latest source record: Nov 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,000
Planned (sponsor's estimate)
Start
Oct 12, 2020
Primary completion
Oct 30, 2021
Study completion Nov 30, 2021
Sponsor
- Lead sponsor
- University of PecsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- HECRIN Consortium; Ministry of Innovation and Technology, Hungary
- First posted
- Oct 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open-label, multi-center, interventional safety study of REM therapy in participants 12 years of age or older with COVID-19, pneumonia and oxygen supplementation.
Conditions
- SARS-CoV-2 Infection
Interventions
Remdesivir-HUDrug
Remdesivir-HU 100 mg concentrate for solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability of REM use in Hungary in the conditionally approved indication (EMA)Time frame: 30 days
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Department of Pulmonology Semmelweis University
Budapest, Hungary
National Korányi Institute for Pulmonology
Budapest, Hungary
North - Central Buda Center New St. János Hospital
Budapest, Hungary
Institute of Infectology, University of Debrecen
Debrecen, Hungary
1st Department of Medicine, University of Pécs
Pécs, Hungary
Department of Internal Medicine University of Szeged
Szeged, Hungary
First Department of Internal Medicine, University of Szeged
Szeged, Hungary
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.